Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617500 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP1A2CYP2C9CYP2C19ACLY | |
| SCHEMBL3607091 | 0.81 | CYP1A2 (0.48) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL3617798 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2CYP1A2CYP2C9CYP2C19SHMT2 | |
| SCHEMBL3612420 | 0.75 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL24162679 | 0.74 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL26719555 | 0.74 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL3598992 | 0.73 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL3609801 | 0.73 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2CYP2C9CYP2C19SHMT2 | |
| SCHEMBL3599058 | 0.73 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL3614492 | 0.72 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022541-A1 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | MUTABILIS SA (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022541-A1 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | CBR1, OXER1, CBR3 | SMN1; SMN2 4771/4885CYP1A2 240/4885CYP2C9 270/4885 |
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | SMN1; SMN2 4515/4885CYP1A2 137/4885CYP2C9 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.